Prognostic Impact of Cytogenetic Abnormalities On Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated with Thalidomide-Dexamethasone Incorporated Into Double Autologous Stem-Cell Transplantation: An Analysis of 593 PatientsElena Zamagni, Michèle Cavo, Lucio Catalano et al.|Blood|2010Cited by 7
Incorporation of Thalidomide into Up-Front Double Autologous Stem-Cell Transplantation (ASCT) for Multiple Myeloma Improves the Outcome in Comparison with Double ASCT without Thalidomide. Analysis of Baseline Factors Predicitve of Outcome.Elena Zamagni, Michèle Cavo, Nicoletta Testoni et al.|Blood|2007Cited by 3
Incorporation of Thalidomide-Dexamethasone (Thal-Dex) into up-Front Double Autologous Stem-Cell Transplantation (ASCT) for multiple Myeloma: Final analysis of phase II “Bologna 2002” Study.Elena Zamagni, Michèle Cavo, Nicoletta Testoni et al.|Blood|2009Cited by 1
Baseline Thrombophilic Alterations and Risk of Venous Thromboembolism in 266 Multiple Myeloma Patients Primarily Treated with Thalidomide and High-Dose Dexamethasone.Elena Zamagni, Michèle Cavo, Lelia Valdrè et al.|Blood|2007Cited by 1
Ten Year-Long Term Survival After up-Front Autologous Stem Cell Transplantation in Multiple Myeloma: Results From Two Prospective Clinical TrialsElena Zamagni, Michèle Cavo, Francesco Di Raimondo et al.|Blood|2012Cited by 0